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Abstract: Atrial fibrillation (AF) is the most common cause of cardioembolism. An update on secondary prevention 
strategies, used to protect patients from the risk of stroke in many common cardiac conditions, is presented in the paper. 
The main line of actions of stroke prevention in cardioembolism is mostly connected with antithrombotic drugs, but also 
other, more invasive, techniques are quickly emerging. Also the classic pharmacological prevention with coumarins may 
soon be overcome by new generation anticoagulants. Is an aggressive treatment of Patent Foramen Ovale (PFO) always 
recommended? One of the main challenges of the future years will be to understand competitiveness between old and new 
preventive strategies. 
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INTRODUCTION 
  Cardioembolism accounts for about 20% of all ischemic 
strokes. Cardioembolic strokes are usually severe, prone to 
early recurrence and to hemorrhagic transformation. Also 
long -term recurrence and mortality are higher, probably due 
to the underlying pathogenetic mechanism. Clinical features 
may help to suspect a cardioembolic source, but usually have 
low sensitivity: these could be, sudden onset to maximal 
deficit, quick regression of symptoms, simultaneous or se-
quential strokes in different arterial territories, hemorrhagic 
transformation of an ischemic infarct, early recanalization of 
an occluded vessel. The confirmation of the cardiac origin or 
its discovery is based on cardiac functional and imaging 
techniques such as electrocardiogram, Holter monitoring, 
echocardiography. Various cardiac conditions have been 
clearly associated with an increase in the risk of ischemic 
stroke (Table 1). Because certain stroke risk factors, like 
hypertension, may also be determinants of cardiac disease, 
some cardiac conditions may be viewed as intervening 
events in the causal chain for stroke. Cardiac factors that 
independently increase the risk of stroke include AF, valvu-
lar heart disease, myocardial infarction, coronary artery dis-
ease, congestive heart failure [1, 2]. Improved cardiac imag-
ing has led to increased detection of potential predisposing 
conditions, such as patent foramen ovale (PFO), atrial septal 
aneurysms, aortic arch atherosclerotic disease, mitral anular 
calcification, spontaneous left atrial appendage echo contrast 
and valvular strands (thin filamentous material). Consider-
able advancements in relation to some cardioembolic condi-
tions have occurred in recent years, especially in atrial   
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fibrillation (AF), several evidence-based treatment strategies 
have emerged and novel therapeutic options will be available 
for the future. For other cardioembolic disorders there are 
still partial knowledge and conflicting opinions that limit the 
establishment of defined guidelines. This chapter provides an 
overview of the current state of knowledge for the major 
cardioembolic stroke risk factors and the strategies of pri-
mary and secondary prevention with particular interest to 
future therapeutical perspectives.  
Table 1.  Cardiac Risk Factors for Ischemic Stroke 
 
DEFINITE POSSIBLE/PROBABLE 
Atrial Atrial 
Atrial Fibrillation  Patent foramen ovale 
Substained atrial flutter  Atrial septal aneurysm 
Sick sinus syndrome 
Atrial mixoma 
Atrial or ventricular septal defects 
Left atrial appendage thrombus  Spontaneous echocontrast in left 
atrial appendage 
Ventricular Ventricular 
Acute myocardial infarction 
Left ventricular failure 
Subaortic hypertrophic car-
diomiopathy 
Left ventricular thrombus  Cardiac valves 
Dilated myocardiopathy  Mitral valve prolapse 
Cardiac valves  Calcified aortic stenosis 
Mitral stenosis/calcifications  Valve strands 
Prosthetic valves  Fibroelastoma 
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ATRIAL FIBRILLATION (AF) 
  Atrial Fibrillation is the most important cause of cardi-
oembolic stroke. In Western countries AF is mainly associ-
ated with hypertensive and ischemic heart disease, but it can 
also occur in absence of any cardiac pathology (lone AF), 
while rheumatic mitral valve disease seems to be now very 
rare in industrialized areas. For this reason the following 
paragraphs relates only to non-valvular AF. The overall 
prevalence is approximately 1%, but the prevalence among 
those older than 65 years is close to 6%. Therefore, the at-
tributable risk of stroke due to AF increases significantly 
with age, approaching the risk of hypertension among pa-
tients 80 to 89 years old. Approximately, 16% (11% to 29%) 
of all ischemic strokes are associated with AF [3], and 
among patients over 70 years old with ischemic stroke, more 
than one-third suffer from AF [1]. AF increases the relative 
risk of ischemic stroke about five-fold, roughly 1% to 5% 
per year for elderly people [3]. Loss of atrial contraction in 
AF leads to blood stasis, particularly, in the left atrial ap-
pendage which is a known pro-thrombotic condition.  
Standards in Cardioembolism Prevention 
  Prevention of systemic embolism is achieved by means 
of restoration and control of sinus rhythm or with permanent 
anti-thrombotic treatment. Concerning the selection of the 
most appropriate antithrombotic regimen, clinical trials 
demonstrated that anticoagulation is more effective than as-
pirin. Five trials of primary prevention (AFASAK, SPAF I, 
BAATAF, CAFA, SPINAF) comparing warfarin vs. placebo 
found a relative risk reduction of 2.5% to 4.7% per year for 
ischemic stroke and absolute stroke rate reduction of 33% to 
86% [3]: a recent meta-analysis of anti-thrombotic therapies 
for primary and secondary prevention of stroke in AF by 
Hart and collegues [4] confirmed the relative reduction in 
stroke risk with warfarin compared to placebo (64%; 95%CI 
49% to 74%). The meta-analysis also showed a lower reduc-
tion in the relative risk of stroke when using antiplatelet ther-
apy (8 trials, 4876 participants): 22% (95%CI 6% to 35%) 
[4]. Comparing directly warfarin with anti-platelet drugs, 
alone or in combination (e.g. aspirin plus clopidogrel in the 
ACTIVE W trial), the anticoagulation therapy reduced the 
relative risk of stroke of 39% (95%CI 22% to 52%; 12 trials, 
12963 patients) [4]. Therefore the meta-analysis by Hart and 
colleagues validates that warfarin is more efficacious than 
aspirin in stroke risk reduction in primary and secondary 
prevention studies. The combination of warfarin plus anti-
platelet drugs was tested versus warfarin alone in a meta-
analysis of ten randomized trials by Dentali and collegues 
[5], but it didn’t show an additive beneficial effect, while the 
risk of bleeding was increased in patients receiving the 
the combination therapy (1.43; 95%CI 1.00 to 1.25). Only 
the study NASPEAF [6] (National Study for Primary Pre-
vention of Embolism in Non-rheumatic Atrial Fibrillation) 
reported a reduction in vascular events in the group of the 
combination of triflusal and acenocoumarol compared with 
warfarin alone (hazard ratio 0.33; 95%CI 0.12-0.91).  
  The beneficial effect of warfarin in stroke risk prevention 
must be balanced with the risk of hemorrhage complications. 
The absolute risk of hemorrhage in patients with AF on war-
farin calculated from randomized clinical trials averaged 2% 
per year, one quarter of which (0.3% to 0.6%) were intra-
cranial haemorrhage [7, 8]. The risk of intra-cranial hemor-
rhage was doubled with warfarin compared with aspirin, 
although the increase in absolute risk was small (0.2% per 
year). In the BAFTA (Birmingham Atrial Fibrillation Treat-
ment of the Aged study) [9], a randomized clinical trial of 
warfarin versus aspirin in the elderly (age>75 years), the risk 
of hemorrhage was similar in both treatment groups, raising 
concern of possible selection bias like restriction to patients 
with moderate risk of stroke.  
Risk Stratification for Patients with AF 
  Assessment of thromboembolic risk in AF is essential to 
guide the use of anticoagulation or anti-platelet therapy. In a 
recent systematic review of risk factors for stroke in AF pa-
tients, four clinical features emerged as consistent predictors: 
prior TIA or stroke (RR 2.5, 95%CI 1.8 to 3.5), increasing 
age (RR 1.5 per decade, 95%CI 1.3 to 1.7), history of hyper-
tension (RR 2.0, 95%CI 1.6 to 2.5) and diabetes mellitus 
(RR 1.7, 95%CI 1.4 to 2.0) [10]. Several risk factors stratifi-
cation schemes (CHADS2, SPAF, AFI1, Framingham, 
ACCP, ACC/AHA/ESC guidelines, NICE/Birmingham) [11] 
have already been published, but evident differences exist 
between them. The most popular and validated of these 
schemes is the CHADS2 [11] (see Table 2) which relies on 
the previous four clinical predictors plus congestive heart 
failure, making its use simple for everyday clinical practice. 
Other variables that could ameliorate the risk stratification 
have been investigated, but conflicting results have been 
reported. Among these, echocardiographic findings: a pooled 
analysis of three studies, BAATAF, SPINAF, and SPAF I, 
showed that moderate to severe left ventricular dysfunction, 
but not left atrial size, was an independent predictor of stroke 
[12]; Shively and collegues [13] noted increased stroke risk 
associated with decreased left atrial flow velocity (<15 
cm/sec), ventricular dilatation, and decreased left atrial ejec-
tion fraction in patients with AF and atrial enlargement; In 
another study, spontaneous echo contrast was significantly 
associated with AF-related stroke [14].
 Coronary artery dis-
ease and female gender are also less certain risk modifiers, 
Table 2. CHADS2  Scheme 
 
RISK FACTORS  POINTS  TOTAL SCORE  RISK OF STROKE 
Prior stroke or TIA  2 
Age > 75 years   1 
3-6 High   
5.9% - 18.2% per year 
Diabetes mellitus  1 
Arterial hypertension  1 
1-2 Intermediate 
2.8% – 4% per year 
Congestive heart failure  1  0  Low 1.2% -3% per year 58     The Open Neurology Journal, 2010, Volume 4  Giacalone et al. 
but the latter was included as risk factor in two stratification 
schemes (SPAF and Framingham) [11].  
The decision to use anticoagulant or aspirin depends on risk 
stratification of patients with AF. Aspirin carries a lower 
bleeding risk and requires less medical monitoring than do 
anticoagulants, but has a lower stroke risk reduction effect. 
Recent published guidelines for the management of atrial 
fibrillation [15], in particular for stroke prevention, recom-
mend the use of anticoagulation in patients with more than 1 
moderate risk factors (age 75 years or older, hypertension, 
heart failure, ejection fraction below 35% or fractional short-
ening less than 25% and diabetes mellitus) (level of evidence 
A). Aspirin, 81–325 mg daily, is recommended as an alterna-
tive to vitamin K antagonists in low-risk patients or in those 
with contraindications to oral anticoagulation (level of evi-
dence A). For patients with less validated risk factors or with 
only 1 risk factor it is reasonable to choose the anti-
thrombotic therapy based upon an assessment of the risk of 
bleeding complications, ability to safely sustain adjusted 
chronic anticoagulation, and patient preferences (level of 
evidence A). The same criteria in selecting the anti-
thrombotic therapy should be used irrespective of the pattern 
(i.e., paroxysmal, persistent, or permanent) of AF (level of 
evidence B). 
When to Start with Anticoagulation? 
  The issue of when to initiate anticoagulation treatment in 
a patient with AF with stroke or TIA is extremely important 
on the light of the high risk of stroke recurrence in the first 
two weeks and of the high risk of haemorrhagic transforma-
tion of the cerebral infarct (Fig. 1). The recent meta-analysis 
by Paciaroni and collegues [16] and the update by Guedes 
and Ferro [17], addresses this issue evaluating 8 randomized 
trials comparing anticoagulants (unfractionated heparin or 
low-molecular-weight heparin or heparinoids) started in the 
first 48 hours with other treatments in patients with acute 
ischemic cardioembolic stroke. The results of the meta-
analysis didn’t show a significant reduction in recurrent 
ischemic stroke within 7 to 14 days with anticoagulation 
compared with other treatments (3.0% versus 4.9%. OR 
0.68, 95% CI 0.44 to 1.06, p=0.09), while the symptomatic 
intracranial bleeding were increased with early anticoagula-
tion therapy (2.5% versus 0.7%, OR 2.89, 95% CI 1.19 to 
7.01, p=0.02). Death or disability at final follow up were 
similar in the two groups (73.5% versus 73.8%, OR 1.01, 
95%IC 0.82 to 1.24, p=0.9). The difference in death and dis-
ability was statistically significant in only one trial (58.5% 
versus 74.1%, OR 0.49, 95%IC 0.26 to 0.93) [18] which was 
the only study with anticoagulation therapy started within 3 
hours from stroke onset. The positive effect of early heparin 
could be ascribed, as suggested by several studies [19, 20], 
also to its anti-inflammatory properties than to its anti-
thrombotic ones. However additional clinical trials in the 
three-hour period are needed to confirm this finding. Current 
guidelines and usual practice recommend that anticoagula-
tion should be started as soon as possible in patients with AF 
after brain imaging for a TIA and should be delayed in 
ischemic stroke, according to ischemic lesion extension, 
clinical severity and cardiologic comorbidity, stroke in fa-
vour of anti-platelet therapy [1, 21]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Cardioembolic stroke: left hemispheric middle cerebral 
artery infarction with visible bleedings (petecchiae) and sulci   
effacement. 
 
Future Treatment Perspectives in AF 
  Future strategies for stroke prevention in AF include i) 
fixed low-dose warfarin anticoagulation; ii) new oral antico-
agulant drugs; iii) non-pharmacological approaches.  
  One meta-analysis reported that fixed low-dose warfarin 
compared with adjusted-dose warfarin was associated with 
more thromboembolic events without reducing the risk of 
bleeding complications [22]. New oral anticoagulant drugs 
are currently in development owing to the many limitations 
of vitamin K antagonists. There are two main types of these 
agents: direct thrombin inhibitors (DTIs) and oral factor Xa 
inhibitors (FXaI). The first DTI tested was ximelagatran, that 
showed in a phase III clinical trial a significant reduction in 
terms of prevention of stroke in AF compared to warfarin, 
but was then abandoned because of hepatotoxicity in a sub-
stantial number of patients [11]. Others DTIs like dabigatran 
and megalatran are currently under investigation. Dabigatran 
has been recently investigated in the RE-LY trial [23], which 
randomly assigned 18,113 patients who had atrial fibrillation 
to receive fixed doses of dabigatran (110 mg or 150 mg 
twice daily) or adjusted-dose warfarin: the risk of stroke was 
reduced in patients receiving dabigatran at a dose of 150 mg 
twice daily respect to warfarin (95% CI 0.53 -0.82, p<0.001 
for superiority) and the risk of major bleedings was reduced 
in patients receiving 110 mg of dabigatran twice daily re-
spect to warfarin (p=0.003); the study also demonstrated the 
non-inferiority of the 110 mg dose of dabigatran versus war-
farin in stroke reduction and of the 150 mg dose of dabiga-
tran versus warfarin in major bleeding risk. The major ad-
vantage of dabigatran respect to warfarin is that it doesn’t 
need dose adjustment and therefore it should be less prone to 
inadequate anticoagulation. The parenteral FXaI idraparinux 
has been compared to warfarin in the AMADEUS trial in 
patient with AF, but clinically bleeding complications were 
significantly higher in the idraparinux group (19.7% vs 
11.3%, p=0.007) and the drug achieved the criteria of non-
inferiority [24]. Other oral FXaI like rivaroxaban and apixa-
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orally active, selective, reversible FXa inhibitor, DU-176b 
[N-(5-Chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(N,Ndimethylcar-
bamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo [5,4-c]pyri-
dine-2carboxamido)cyclohexyl]ethanediamide p-toluenesul-
fonate monohydrate], is currently under investigation. In 
non-clinical studies [25, 26], DU-176b showed excellent 
potential as an antithrombotic agent. Non-clinical data indi-
cate no evidence of liver function abnormalities in study 
animals exposed to DU-176b. In Japan, two early phase 2a, 
DU-176b, open-label, dose-escalation studies were con-
ducted in a total of 56 subjects with nonvalvular AF. Sub-
jects were treated for 6 to 10 weeks with total daily doses of 
5 mg to 120 mg: the doses evaluated in this study were well 
tolerated, no major bleeding was reported. There was one 
clinically relevant non-major bleeding reported for each of 
the following DU-176b regimens: 30 mg bid, 45 mg bid, and 
60 mg bid [26]. There were no others observed clinically 
relevant liver function abnormalities. A phase 3, randomized, 
double-blind, double-dummy, parallel-group, multi-center, 
multi-national study for evaluation of efficacy and safety of 
DU-176b versus warfarin in subjects with atrial fibrillation, 
ENGAGE AF-TIMI48 trial (Effective Anticoagulation with 
factor xA next Generation in Atrial Fibrillation) is currently 
ongoing: data from this study are expected for 2011. 
  The non-pharmacological approaches for stroke preven-
tion can be divided in an electrophysiological approach like 
ablation techniques with the aim of restoring the sinus 
rhythm and a mechanical approach with the aim of prevent-
ing the formation of thrombus in left atrium appendage or to 
divert it from the cerebral circulation.  
  The electrophysiological approach is based on two types 
of ablation procedures, the “maze” procedure that involves 
complex lesioning of the left atrium and the pulmonary veins 
isolation [27]. In selected series the pulmonary veins isola-
tion appears to prevent symptomatic AF in 80% to 90% at 1 
year of follow-up [1, 27], but there are no data about the du-
rability of this effect.  
  The rationale behind the mechanical approach is that the 
most of thrombi that then embolise originates from the left 
atrium appendage where there is an hypercoagulable state 
because of the blood stasis. Today, surgical excision of the 
left atrium appendage is routinely performed as an adjunct to 
cardiac surgery in those cases at high risk for left atrium ap-
pendage-related thromboembolism. The North American 
guidelines for management of patients with valvular heart 
disease recommend amputation of the left atrium appendage 
at the time of mitral valve surgery to reduce the risk of stroke 
[28]. Exclusion of the left atrium appendage can also be per-
formed thoracoscopically under general anesthesia by apply-
ing a loop snare or by stapling the base of the left atrium 
appendage. Occlusion, as opposed to ligation or amputation, 
of the left atrium appendage can also be performed using 
three percutaneous-catheter-based systems: the Percutaneous 
Left Atrial Appendage Transcatheter Occlusion (PLAATO
®) 
system, the WATCHMAN
® system and the AMPLATZER
® 
[28]. The development of left atrium appendage occlusion 
systems provides a promising alternative to anticoagulation, 
specially for patients at high risk of AF-related stroke who 
cannot tolerate anticoagulation. However safety and effec-
tiveness must be still verified by additional studies. In initial 
studies, complications requiring surgical exploration (e.g. 
device embolisation, pericardial tamponade, stroke, and 
death) occurred at higher than acceptable frequencies [28].  
PATENT FORAMEN OVALE (PFO) 
  During the last decade, there has been an increasing em-
phasis on the role of patent foramen ovale (PFO) in the 
genesis of ischemic juvenile stroke. Several case control 
studies and a meta-analysis [29,30] have shown that PFO 
was significantly associated with stroke in patients younger 
than 60 years of age, in particular in the subgroup of young 
patients with cryptogenic stroke. A recent case-control study 
by Handke and collegues [31] has shown that also in the age 
group of patients older than 55 years with cryptogenic stroke 
the prevalence of PFO was significantly greater than in pa-
tients with non-cryptogenic stroke with an odds ratio after 
the multivariate analysis of 3.00 (95%CI, 1.73 to 5.23; 
p<0.001) [31]. The previous meta-analysis by Overell and 
collegues [29] didn’t show a significant risk associated with 
PFO in patient older than 55 years with cryptogenic stroke 
based on three studies (only one of these studies had shown a 
significant risk in patients older than 55 years) [32]. In the 
study by Homma and collegues [33] in an exploratory analy-
sis of patients with cryptogenic stroke from the PICSS study 
(PFO in Cryptogenic Stroke Study), the PFO significantly 
increased the risk of adverse events at two years of follow-up 
in patients older than 65 years but not in patients younger 
than 55 years (p=0.01; hazard ratio 3.21; 95% CI, 1.33 to 
7.75). The controversial findings of these studies have raised 
concern in commentaries about the selection of the study 
populations and further studies are needed to investigate the 
issue. Cerebral paradoxical embolism is usually a presumed 
diagnosis, because direct evidence, such as a thrombus 
lodged in the PFO shown on transesophageal echocardiogra-
phy or the discovery of a deep venous thrombosis, is com-
monly lacking. Despite these ongoing controversies, it is 
reasonable to incriminate a cerebral paradoxical embolism in 
young patients with no other identified cause of stroke than 
PFO. 
  The optimal treatment of these patients remains a matter 
debate, mainly because of a lack of controlled clinical trials. 
There are four therapeutic options: antiplatelets drugs, anti-
coagulants, closure of PFO by transcatheterization or closure 
of PFO by surgery. The only two studies [34,35] of secon-
dary prevention of stroke in patients with PFO show that the 
risk of recurrent stroke is relatively low, about 1% per year, 
in patients treated with aspirin or short-term anticoagulation. 
In the Lausanne Study [34] and the French Study Group 
[35], the annual rate of TIA was 3.8% and 3.4%, of stroke 
alone, 1.9% 1.2%, respectively. 
  At present, there is little information on the risk of stroke 
recurrence in those with PFO associated with an atrial septal 
aneurysm (ASA) compared to PFO alone, and some have 
suggested that PFO with an ASA, or large PFOs with right-
to-left shunting, have more stroke risk [36, 37]. Several fac-
tors have been suggested to increase the risk for stroke or 
recurrent stroke in patients with PFO: these includes a 
younger age [29], the association with atrial septal aneurysm 
(ASA) [29, 38], the presence of a right-to-left shunt at rest, 
the size of the PFO [39, 40], the association with thrombo-
philic conditions [41]. Despite a meta-analysis and other 
studies have reported a strong increase in stroke risk and 
stroke recurrence in patients with both PFO and ASA com-60     The Open Neurology Journal, 2010, Volume 4  Giacalone et al. 
pared with PFO alone, specially in cryptogenic stroke, other 
studies failed to confirm this association [32, 33]. Also for 
the other presumed risk factors further evaluations are 
needed because of controversial findings. On these grounds, 
Nendaz et al. [42] created a decision analysis model for the 
clinician. This model indicates that for a stroke risk recur-
rence of 1.4% to 7% per year, there was more benefit from 
surgical closure of the PFO than from any other treatment. 
When the risk is from 0.8% to 1.4% per year, anticoagulants 
and antiplatelets are better than placebo, while when it is 
<0.8% per year, neither medical nor surgical treatment is 
indicated. Further studies are planned to determine the stroke 
risk in subgroups of PFO patients using transcranial Doppler 
ultrasound with the microbubble technique, which may be 
more accurate than transesophageal echocardiography [43]. 
At present, treatment is limited to the application of empiri-
cal clinical criteria. Useful clarifications for the best ap-
proach in the long- term management of PFO with TIA or 
stroke could come from the epidemiological data of the Fo-
rame Ovale Registro Italiano (FORI), a multicentric registry 
based in Perugia, established in 2003.  
  Surgical closure of PFO without stroke recurrence has 
been reported [44, 45], but others have not been so fortunate 
[46]. A minimally invasive alternative to surgery consists in 
transcatheter closure of the PFO. The procedure involves the 
percutaneous implantation of a device to occlude the in-
teratrial septum (CardioSEAL
® and Amplatzer
®, approved 
by FDA). The reported complications following PFO closure 
are infrequent and are associated with low morbidity and 
mortality. Adverse events includes brief atrial fibrillation 
(0.8%), device dislodgement (0.4%), device arm fracture 
(3.6%) and surgical explanation (0.8%) [47]. However long-
term consequences of PFO closure are unknown. A review 
of 12 uncontrolled case series of more than 100 patients 
documented a rate of stroke recurrence during the first year 
after transcatheter PFO closure between 0 and 5% [46]; the 
percentages during the other years of follow-up varied con-
siderably between the different studies. Current data suggest 
that transcatheter closure is at least effective as medical 
treatment, but further studies are necessary to investigate this 
issue. 
  The use of coumarins is risky in young patients with a 
long life expectancy because of the major bleeding risk, es-
timated at 1.5% to 11% per year [45]. The ACCP guidelines 
[48] recommend anti-platelet therapy in patients with 
ischemic stroke and PFO; anticoagulants are recommended 
when a deep venous thrombosis (DVT) is demonstrated by 
ultrasound investigation or by venography, when there is 
association with an underlying hypercoagulable state and 
before closing the PFO in those with a presumed higher risk 
of stroke recurrence. PFO closure might be considered for 
patients with recurrent cryptogenic ischemic strokes, despite 
antithrombotic therapy or after the first event in patients with 
high-risk conditions such as presence of DVT, hypercoagu-
lable state, characteristic of PFO documented by trans-
esophageal echocardiography. In practice, and until results of 
future studies focusing on risk stratification are reported, the 
following criteria could be applied to decide secondary pre-
vention therapy in patients with stroke and PFO (Table 3): 
(1) more than one cerebrovascular event clinically or on MRI 
scan, (2) evidence of DVT, (3) demonstration of an hyperco-
agulable state, (4) significant right-to-left shunting through 
the PFO documented by echocardiography or Doppler, (5) 
PFO associated with ASA and (6) a history of Valsalva's 
manoeuvre just before the clinical event. 
PROSTHETIC HEART VALVES (PHV) 
  In the last decades the replacement of heart valves con-
stantly increased: considering only aortic valve disease, more 
than 200,000 replacements are currently performed annually 
worldwide [49].  
  In patients with prosthetic heart valves, thromboembolic 
events occur at a rate of 7 to 34% per year without antico-
agulant therapy and at a rate of 1 to 5% per year with oral 
anticoagulation [50]. Two types of PHV are used: biopros-
thetic valves and mechanical valves. Both mechanical and 
bioprosthetic valves are at increased risk of stroke, which 
however is confined in the latter to the first months after 
implantation, while it is long-lasting in the former; the last 
decade have seen a dramatic reduction in the use of me-
chanical valves (aortic valve: 21% mechanical vs. 79% of 
Table 3.  Secondary Prevention in Patients with PFO-Associated Stroke: Risk Stratification-Based Recommendations 
 
RISK STRATIFICATION  HIGH RISK  MODERATE RISK  LOW RISK 
Absolute criterion 
No other potential cause of stroke than PFO 
 
Required 
 
Required 
 
Required 
Major criteria 
Evidence of deep vein thrombosis 
Evidence of a hypercoagulable state 
Stroke recurrence despite antithrombotic treatment 
 
1 criterion 
 
1 criterion 
 
0 criterion 
Minor criteria 
Massive right-to-left shunt 
Interatrial septal aneurysm 
Multiple clinical cerebrovascular events and/or multiple 
ischemic lesions at brain MRI 
 
1 criteria 
 
0 criteria 
 
0 criterion 
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bioprosthetic [49]; mitral valve: 55% repair techniques, 28% 
mechanical, 17% bioprosthetic [51]) mostly because of the 
need of a life-long anticoagulant therapy. Thromboembolic 
risk associated with PHV is also related to the site of valve 
replacement, being higher for mitral valve than for aortic 
valve, and to the kind of mechanical valve used, being lower 
for the bileaflet ones than for monoleaflet and caged ball 
ones. The presence of other risk factors, such as AF, left ven-
tricular dysfunction, spontaneous echocardiographic contrast 
in the left atrium and increasing age obviously also increase 
the chance of embolism [52].
 Stroke may occur from either 
inadequate anticoagulation or because thrombogenic factors 
are inadequately suppressed despite adequate anticoagulation 
therapy. The precise pathophysiology of thromboembolism 
in patients with PHV remains uncertain. Increased shear 
rates at the valve surfaces may activate platelets, generating 
platelet-derived microparticles, which could have potent 
procoagulant activity. Furthermore, the presence of micro-
emboli, frequently encountered in these patients, may result 
from harmless gaseous bubbles (cavitation) [53]. 
  As yet, no prospective randomized studies have been 
done in patients with mechanical valves to assess the effi-
cacy of antithrombotic therapy. In a meta-analysis compris-
ing more than 53,000 patient-years, the major embolism rate 
without antithrombotic therapy was 4.0% per year, reduced 
to 2.2% year with antiplatelets and to 1.0% per year with 
anticoagulants [50]. Current guidelines of the ACCP [48] 
recommend the use of anticoagulation with an INR range of 
2 to 3 for bileaflet mechanical aortic valves, with an INR 
range of 2,5 to 3,5 for mechanical mitral valves and for 
monoleaflet valves; in case of stroke during anticoagulation 
or if there are concomitant vascular risk factors, it is recom-
mended the use of anti-platelet therapy like aspirin 75-
100mg per day in addition to anticoagulation (INR range 2,5 
to 3,5); in patients with bioprosthetic valves it is recom-
mended anticoagulant therapy for the first 3 months after 
implantation followed by anti-platelet therapy. 
ACUTE MYOCARDIAL INFARCTION (AMI) 
  About 1% to 5% of patients with AMI have an ischemic 
stroke, most of them cardioembolic, occurring within two to 
four weeks. Stroke occurred especially in those with anterior 
AMI, in whom the risk of ischemic stroke raises to 12% [3], 
and in patients with large anterior infarcts [54]. In the first 
month after AMI, incidence rates were 1% to 3.2%, and AF 
and ST segment elevation were significant predictors [55]. 
Left ventricular thrombi, in older patients with large trans-
mural infarcts, especially those with congestive heart failure, 
have an increased risk of stroke. Transesophageal echocardi-
ography is needed to diagnose ventricular thrombosis, but it 
should be performed at least 24 hours after AMI, because 
these develop usually 1 to 10 days after AMI. Approximately 
15% of AMI patients with recognized LVT will suffer stroke 
[3]. No randomized trials have been carried out comparing 
aspirin to anticoagulants to prevent stroke following AMI, 
though anticoagulants alone were shown effective in pre-
venting recurrent AMI (INR 2.8 to 4.8) and stroke in the 
Anticoagulants in Secondary Prevention of Events Coronary 
Thrombosis (ASPECT) trial. No comparison with aspirin 
was ever made [56]. Early randomized trials showed that 
heparin followed by low-intensity oral anticoagulation (INR 
1.6 to 2.5) reduced stroke by about 70% in the weeks follow-
ing AMI [3]. Being stroke rate three months after AMI so 
low, long-term anticoagulation beyond three months is not 
justified unless other major cardiac embolic risk factors, 
such as mural thrombosis, are present. 
OTHER CARDIAC ARRHYTMIAS  
  Data concerning Atrial Flutter and Atrial Fibrillation-
Flutter are scarce, and the exact risk of stroke associated with 
these conditions is unknown. Nevertheless, in a recent small 
study in patients without history of brain ischemia, the an-
nual risk of stroke was only 1.6% [57]. In a recent prospec-
tive study of sick sinus syndrome (SSS), previous cerebral 
ischemic events, an age >65 years, left atrial spontaneous 
echocardiographic contrast and depressed atrial ejection 
force were independent risk factors for stroke [59,60]. Those 
with AF showed a thromboembolic rate of 5% per year, 
compared to 3.5% per year in those without AF [3], though a 
more recent study reported stroke rate of 10% per year 
[58,59]. Dual-chamber cardiac pacemakers reduced both the 
occurrence of AF as well as thromboembolism in compari-
son to ventricular pacing. For secondary prevention in pa-
tients with well established SSS, anticoagulation should be 
considered, irrespective of the presence or absence AF [3]. 
The value of antiplatelets, the optimal intensity anticoagula-
tion, and the safety chronic anticoagulation in elderly pa-
tients still remains uncertain. 
CONCLUSIONS 
  During the last decades many efforts have been focused 
on AF, by far the commonest cause of cardioembolic stroke, 
to establish evidence-based recommendations for primary 
and secondary stroke prevention: the use of long-term anti-
coagulation (INR 2–3) substantially reduced stroke recur-
rence risk and is now clearly established as a powerful 
treatment strategy; furthermore individualized treatment de-
cisions based on risk factor stratification schemes like 
CHADS2, are now widely accepted and available to simply 
guide the clinician in the optimal anti-thrombotic strategy. 
On the other hand, however, there is still partial knowledge 
and conflicting results for other cardiac disorders like PFO, 
for which, although the real pathogenetic weight is still un-
known, several aggressive treatment strategies, like implan-
tation of cardiac devices for life-time, are quickly spreading 
in current clinical practice. Can the risk of unpredictable 
potential long-term complications be balanced by the treat-
ment of a still partial known pathogenetic factor? Novel 
large, controlled clinical trials and the creation of large, dis-
eases registries are expected to answer to these important 
questions. But above all, the hope for the next decade is di-
rected to the development of new generation anticoagulants 
which could revolutionize the cardioembolic prophylaxis. 
ABBREVIATIONS 
AF =  Atrial  fibrillation 
PFO  =  Patent foramen ovale 
MRI =  magnetic  resonance  imaging 
DTIs  =  direct thrombin inhibitors 
FXaI  =  factor Xa inhibitors  
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DVT =  deep  venous  thrombosis 
PHV  =  prosthetic heart valves 
INR =  International  Normalized  Ratio 
AMI  =  Acute myocardial infarction  
SSS  =  sick sinus syndrome 
ACCP  =  American College of Chest Physicians 
ACC/AHA/  =  American College of Cardiology/American  
ESC     Heart  Association/  European Society of 
Cardiology 
AFASAK  =  Atrial Fibrillation, Aspirin, and Anticoagu-
lant Therapy Study 
SPAF I  =  The Stroke Prevention in Atrial Fibrillation 
Study 
BAATAF  =  Boston Area Anticoagulation Trial for Atrial 
Fibrillation 
CAFA  =  Canadian Atrial Fibrillation Anticoagulation 
SPINAF  =  Silent Cerebral Infarction in Patients With 
Nonrheumatic Atrial Fibrillation 
ACTIVE  W = Atrial Fibrillation Clopidogrel Trial with 
Irbesartan for Prevention of Vascular Events 
NASPEAF  =  National Study for Primary Prevention of 
Embolism in Non-rheumatic Atrial Fibrilla-
tion 
BAFTA  =  Birmingham Atrial Fibrillation Treatment of 
the Aged study 
CHADS2  =  Congestive heart failure, Hypertension, Age, 
Diabetes mellitus, Stroke 
RE-LY  =  Randomized Evaluation of Long-term anti-
coagulation therapY 
ENGAGE  =  Effective aNticoaGulation with factor xA 
next GEneration in Atrial Fibrillation 
FORI  =  Forame Ovale Registro Italiano 
ASPECT  =  Anticoagulants in Secondary Prevention of 
Events Coronary Thrombosis 
PLAATO
®.  =  Percutaneous Left Atrial Appendage  
system   Transcatheter  Occlusion 
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